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Abstract
Background: Transmissible spongiform encephalopathies are fatal neurodegenerative disease occurring in animals
and humans for which no ante-mortem diagnostic test in biological fluids is available. In such pathologies,
detection of the pathological form of the prion protein (i.e., the causative factor) in blood is difficult and therefore
identification of new biomarkers implicated in the pathway of prion infection is relevant.
Methods: In this study we used the SELDI-TOF MS technology to analyze a large number of serum samples from
control sheep and animals with early phase or late phase scrapie. A few potential low molecular weight biomarkers
were selected by statistical methods and, after a training analysis, a protein signature pattern, which discriminates
between early phase scrapie samples and control sera was identified.
Results: The combination of early phase biomarkers showed a sensitivity of 87% and specificity of 90% for all
studied sheep in the early stage of the disease. One of these potential biomarkers was identified and validated in a
SELDI-TOF MS kinetic study of sera from Syrian hamsters infected by scrapie, by western blot analysis and ELISA
quantitation.
Conclusions: Differential protein expression profiling allows establishing a TSE diagnostic in scrapie sheep, in the
early phase of the disease. Some proteic differences observed in scrapie sheep exist in infected hamsters. Further
studies are being performed to identify all the discriminant biomarkers of interest and to test our potential markers
in a new cohort of animals.
Background
Scrapie is a well-known prion-associated sheep encepha-
lopathy that was identified in the XVIII century. Scrapie
is a fatal neurodegenerative disease and related forms
affect also humans (i.e., Creutzfeldt-Jakob disease) and
cattle (i.e., bovine spongiform encephalopathy). It is
characterized by accumulation in the central nervous
system of a pathological agent, the prion protein (PrP
Sc)
[1], which differs from the endogenous normal form
(PrP
c) in conformational changes, partial resistance to
proteolytic degradation and insolubility in the presence
of detergents [2,3]. Scrapie is a good model to study
transmissible spongiform encephalopathies (TSEs) since
the disease is related to genetic factors. The natural
occurrence of scrapie is associated with the PRNP
genotype at positions 136, 154, 171 [4-6]. Specifically,
infected animals present the homozygous PrP
VRQ/
PrP
VRQ genotype, whereas healthy ones the homozygous
PrP
ARR/PrP
ARR genotype. The incidence of the pathol-
ogy is predicted as 100% for PrP
VRQ/PrP
VRQ animals
whilst PrP
ARR/PrP
ARR animals are considered resistant
[7-10]. However, few cases of scrapie in PrP
ARR/PrP
ARR
sheep have been reported with biochemical and trans-
mission characteristics similar to those of classic scrapie,
although PrP
Sc was associated with lower proteinase
K-resistance [11,12]. In contrast to BSE, scrapie is asso-
ciated with wide PrP
Sc dissemination in many non-
neural tissues including the lymphoreticular system, the
kidney and the placenta [13]. The incubation period of
the disease is long and silent (i.e., early, replicative phase
of PrP
Sc) and clinical symptoms appear in sheep aged
from twelve to fifteen months (i.e., late, neuroinvasion
phase of the disease). PrP
Sc can be detected in PrP
VRQ/
PrP
VRQ sheep two months after infection [14]. Between
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agent is detected essentially in lymphoid formations
associated to the gastrointestinal tract. From six to nine
months the secondary lymphoïd organs are also infected
and finally at the tenth month after infection the central
nervous system is affected [6,10,15].
At the moment, unambiguous diagnosis is only possi-
ble post-mortem and it is based on the detection of PrP
Sc
after proteolytic digestion. A complementary diagnostic
evaluation can be performed by immunohistochemistry,
western blot or ELISA but none of these methods can
detect scrapie during the incubation period without
autopsy. Since PrP
Sc can accumulate in lymphoid tissues
before spreading to the nervous system and this accumu-
lation can be very extensive, some authors have proposed
using this tissue for the in vivo and post-mortem diagno-
sis of scrapie [16-20]. However, the sensitivity of this
methodology is not well characterised because the mag-
nitude and duration of lymphoid tissue involvement can
vary considerably [21].
The diagnosis of TSEs during the early phase by a
rapid test performed in blood is thus required because
of the existence of the variant Creutzfeldt-Jakob disease
in humans and its possible iatrogenic transmission by
blood [22]. Currently, several candidate ante-mortem
biomarkers from serum, cerebrospinal fluid or tissue
have been identified (i.e.,14.3.3 protein [23], NSE
[24,25], S100B proteins [26,27], tau proteins [28-31],
apolipoprotein E [32], C reactive protein and IL-6 [33],
cystatin C [34], EDRF [35,36]), but none of them is spe-
cific or sensitive enough to be used in a routine diag-
nostic test. The only useful marker for diagnostic tools
still is PrP
Sc [37,38], but its application in an ante-
mortem test of prion disease in animals and humans, as
proposed by Castilla and collaborators [39,40], with the
“Protein Misfolding Cyclic Amplification”, is still diffi-
cult and no significant results are available yet. A new
detection method of disease-associated multimeric
forms of the prion protein in plasma of prion-affected
hamsters and sheep is called ‘Multimer Detection Sys-
tem’ [41]. The first results provided have now to be con-
firmed. Recently, the PrP
Sc has been detected in blood
from sheep infected with scrapie and bovine spongiform
encephalopathy [42] and in milk from ewes incubating
natural scrapie [43].
We therefore decided to identify blood proteins that
could be involved in scrapie development by analyzing a
collection of serum samples from healthy and diseased
sheep using proteomic tools. The classical proteomic
tool, the bi-dimensional gel electrophoresis (2-DE) has
been developed 25 years ago. Although this technique
permits a high resolution separation of proteins, sensi-
tivity and reproducibility of these experiments are not
optimal to analyze hundred of highly variable animal
samples. Moreover, 2-DE allows the separation of thou-
sands of proteins but rare proteins are often not
detected and low molecular weight proteins are not
resolved. On the other hand, Surface Enhanced Laser
Desorption/Ionization-time of flight-mass spectrometry
(SELDI-TOF MS, Ciphergen Biosystems, Fremont, CA,
USA), by combining selective protein binding with sen-
sitive and quantitative mass detection, allows the evalua-
tion of protein profiles in a short time from a large
number of samples to identify putative biological mar-
kers [44-46]. SELDI-TOF MS was thus used to charac-
terize the protein profile of sera from sheep at early
(replication) and late (neuroinvasion) stages of scrapie.
This analysis allowed us to identify a combination of
biomarkers that discriminate between early phase (EP)
and late phase (LP) of infection. We then validated
these findings by assessing the appearance of differential
markers in hamsters infected with the 263 K scrapie
strain, a model of prion infection with shorter kinetics
compared to sheep.
Methods
Scrapie evaluation and serum sampling
A total of 163 serum samples of sheep from a naturally
scrapie-affected Romanov flock [14] were used in this
study. Blood samples were collected at the veterinary
laboratory of Toulouse (INRA, France). Sheep were clas-
sified according to their genotype and histopathological
characteristics as shown in Table 1. The sheep in the
early phase of infection (EP) are 7 to 10 months/old,
they were asymptomatic. The sheep in the late phase of
infection (LP) are 13 to 19 months/old and developed
clinical symptoms. We included 78% of females and
22% of males (representative of gender proportion in
this sheep population). The sheep presenting the homo-
zygous PrP
ARR/PrP
ARR genotype are 7 to 94 months/old.
Serum from 3 VRQ/VRQ Cheviot TSE free sheep
(Arthur Rickwood, UK) was collected and included in
the study as a negative control. This flock is the only
source in Europe of sheep free of classical scrapie.
Infection of Syrian hamsters with the 263 K scrapie strain
Infected animals were housed in controlled facilities fully
compliant with the European policy on use of Laboratory
Animals (agreement n°A3 4-175-28). The European
guidelines (EC-86/609) for animal care and experimenta-
tions were followed throughout the duration of the study.
They were identified by electronic chips. Ten age-
matched Syrian hamsters were injected intra-peritoneally
with 5 microliters (μL) (670 micrograms) of homogenate
of brain infected by the 263 K scrapie strain diluted into
95 μL of phosphate buffer saline. 200 mg of infected
brain has been crushed into 1.5 milliliters (mL) of 20%
sucrose. Serum samples were taken at day 0, 29, 57, 106
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the end of the kinetics when it had lost ≈ 30% of its body
weight and was no longer able to remain upright and
feed by itself [47].
Serum protein fractionation
Blood was collected in dry tubes; coagulation was
allowed by incubating samples at 37°C for 30 minutes.
Following centrifugation, sera were immediately stored
at -80°C.
Samples were pre-fractionated by anion exchange
chromatography according to their charge characteris-
tics, using the “Expression Difference Mapping Kit-
Serum Fractionation” from Ciphergen Biosystems.
Briefly, 20 μL of serum were added to each well of a 96-
well culture microplate and proteins were denatured by
addition of 30 μL of 9 M urea, 2% CHAPS, 50 mM
Tris-HCl pH9. Then, each denatured aliquot was trans-
ferred into a filtration microplate containing in each
well Q Hyper D F sorbent beads that had been pre-
viously rehydrated with 200 μL of 50 mM Tris-HCl pH9
(three times) and equilibrated with 1 M urea, 0.2%
CHAPS, 50 mM Tris-HCl, pH9 (three times). In order
to bind sample to sorbent, 50 μL of 1 M urea, 0.2%
CHAPS, 50 mM Tris-HCl, pH9 buffer were added to
each well and mixed for 30 minutes at 4°C. To collect
th e six fractions we added sequentially 200 μLo f
50 mM Tris-HCl with 0.1% OGP, pH9 (Fraction 1, F1)
onto each well of the filtration microplate, then 200 μL
of 50 mM Hepes with 0.1% OGP, pH7 (F2), then 200
μL of 100 mM sodium acetate with 0.1% OGP pH5
(F3), then 200 μL of 100 mM sodium acetate with 0.1%
OGP pH4 (F4), then 200 μLo f5 0m Ms o d i u mc i t r a t e
with 0.1% OGP, pH3 (F5) and finally 200 μL of 33.3%
isopropanol, 16.7% acetonitrile, 0.1% trifluoroacetic acid
(F6, organic wash). Fractions were stored at -80°C.
SELDI-TOF MS analysis of sera
ProteinChip® CM10 (weak cation exchanger, Ciphergen
Biosystems) were pre-treated with 5 μLo f0 . 1Ms o d i u m
acetate, pH4 twice. Five μL of each fraction were diluted
in 5 μL of 0.1 M sodium acetate pH4 for use with weak
cation exchanger (CM10) 8-spot protein chip arrays and
incubated on a shaker in a humidified chamber at room
temperature for 30 minutes. Spots were washed with
5 μL of 0.1 M sodium acetate pH4 twice for 5 minutes,
f o l l o w e db yaq u i c kr i n s ei nd e - i o n i z e dH 2O. After air-
drying, a sinapinic acid solution (70% acetonitrile, 0.1%
trifluoroacetic acid) (SPA, Ciphergen Biosystems), pre-
pared according to the manufacturer’s instructions, was
added to each spot. Arrays were analyzed with a PBS-II
mass reader (Ciphergen Biosystems) using the SELDI
3.2.1 software (Ciphergen Biosystems). We performed
the data acquisition of low molecular weight proteins by
detecting the optimized size range between 2 and 20
kDaltons (kDa) with a maximum size of 30 kDa. Data
were collected by averaging 60 laser shots with an inten-
sity of 260 arbitrary units. The mass-to-charge ratio (m/
z) of each protein captured on the array surface was
determined according to externally calibrated standards
(Ciphergen Biosystems): Hirudin BHVK (7034 Da),
bovine Cytochrome C (12 230 Da), equine Myoglobin
(16 951 Da) and bovine Carbonic Anhydrase (29 023 Da).
Biostatistics analysis
Signal analysis
All spectra were compiled and qualified mass peaks
(signal-to-noise ratio > 5) with mass-to-charge ratios
(m/z) between 2 kDa and 30 kDa were auto-detected.
Peaks clusters were completed using second-pass peak
selection (signal-to-noise > 2) within 0.3% mass win-
dows and estimated peaks were added. To avoid matrix
interference, we removed all signals below 2 kDa and
peaks intensities were normalized to the total ion cur-
rent of m/z between 2 kDa to 20 kDa. Analyses were
performed using the Protein Chip Software 3.2.1
(Ciphergen Biosystems).
Differential analysis of peak intensities
All normalized spectra were exported into an expression
matrix N × M where N represents the mass peak and
M the serum sample; the relative intensity of each peak
is available. Peaks were selected by their statistical sig-
nificance using the “Significance Analysis of Microarray”
method (SAM) [48], a parametric method based on a
modified Student’s t-test currently used in genomic ana-
lysis. Significant peaks were selected when their score
deviated from the average score obtained after 2000 per-
mutations of matrix. The accuracy of markers and their
discriminatory power were evaluated through Receiving
Operating Characteristics (ROC) curves analysis [49].
ROC curves are graphical visualizations of the reciprocal
relation between sensitivity (Se) and specificity (Sp) of a
Table 1 Clinical characteristics of control and diseased sheep
Histopathology Genotype Age in months Sex Strain Number
Controls ARR/ARR 7 to 95 Male and Female Romanov 65
Late phase scrapie (LP) VRQ/VRQ 13 to 19 Male and Female Romanov 43
Early phase scrapie (EP) VRQ/VRQ 7 to 10 Male and Female Romanov 55
total 163
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(AUC) is a good evaluation of the combination of Se
and Sp for a given test.
Statistical validation
The best markers were combined to increase their Se and
Sp with the mROC program [50] and with two super-
vised learning algorithms, AdaBoost [51] and Support
Vector Machine (SVM) [52,53]. The mROC program cal-
culated the linear combination which maximized the area
u n d e rt h eR O Cc u r v ef o ra l ls e l e c t e dv a r i a b l e s( p e a k s ) .
The equation for the respective combination was pro-
v i d e da n dc o u l db eu s e da san e wv i r t u a lm a r k e r .F o ra
marker combination and for a sample selected, the cut-
off was the resulting value of the linear equation corre-
sponding and calculated by the mROC program: Cut-off
=a×M a r k e r 1+b×M a r k e r 2+c×M a r k e r 3 ,w h e r ea ,b
and c are coefficients. For this approach, data were pre-
viously transformed using the Box-Cox transformation to
ensure a normal distribution [54].
The AdaBoost algorithm, short for Adaptive Boosting, is
a machine learning algorithm formulated by Yoav Freund
and Robert Schapire [51]. It is a meta-algorithm and can
be used in conjunction with weak learning algorithms (as
decision tree) to improve their performance. In addition, it
is less susceptible to the overfitting problem than most
learning algorithms. SVM has been recognized as the
most powerful classifier in various applications of pattern
classification. For binary classification, it performs classifi-
cation tasks by constructing hyperplanes in a multidimen-
sional space (via a kernel function) that separate two
classes of data with the maximum margin.
To estimate the errors prediction of these classifiers, we
used the 10-fold cross-validation method. To avoid over-
fitting problems and to reduce variance, we repeated this
10-fold cross-validation procedure 10 times. For this
approach, we used the “ipred package” and the “e1071-
package” of the R software [55].
The p values were calculated by one way ANOVA or
Wilcoxon test with Kaleidagraph 4.0 software.
SELDI peak identification
The libraries of 48 sorbents were obtained from Sigma
Aldrich (St Louis, MO, USA) and from Bio-Rad Labora-
tories (Hercules, CA, USA), as well as materials for elec-
trophoresis such as plates and reagents.
Chromatography purification of the 12 030 Da (S10)
biomarker from crude sample “F6”
After screening the libraries of 48 sorbents (10 μL each)
on a NUNC SilentScreen 96-filter plate at two different
pH binding conditions (5 and 8), two complementary
sorbents were chosen to selectively interact at pH8 with
either the 12 030 Da target (DEAE-Macroprep from
Bio-Rad) or with the target impurities (immobilized
arginine from Sigma Aldrich).
Screening was monitored by SELDI-TOF MS on
CM10 arrays.
First, 500 μL of F6 sample diluted ten times in binding
buffer (0.1 M Tris-HCl pH8, 0.15 M sodium chloride)
were incubated in a Supelco spin column with 1 mL of
arginine sorbent. Non-retained or flow-through fraction
(FT), containing the 12 030 Da target, but now free of key
impurities, was obtained by centrifugation (500 g for
5 minutes). Then, the FT fraction (5 mL) was poured in a
15 mL Falcon tube and 10 μL of DEAE-Macropep sorbent
was added. Incubation was performed by gentle vertical
stirring at room temperature for one hour. After incuba-
tion, FT fractions were centrifuged (1000 g for 10 min-
utes), beads transferred in a 500 μL microtube, extensively
washed with 500 μL of binding buffer and the enriched
12 030 Da biomarker was sequentially eluted with 25 μlo f
the following eluents: a) 4.5 M urea, 1% CHAPS; b) 9 M
urea, 2% CHAPS; c) 9 M urea, 2% CHAPS, 2.4% ammo-
nium hydroxide. Elution was monitored by SELDI-TOF
MS on CM10 arrays, and the most enriched 12 030 Da
fraction (c) selected for final purification on SDS-PAGE
after pH neutralization with acetic acid.
Preparative final purification of 12 030 Da marker
by SDS-PAGE
25 μL of each enriched sample were mixed with 25 μLo f
Laemmli buffer (4% SDS, 20% glycerol, without reducing
agent, 0.004% bromophenol blue and 0.125 M Tris-HCl,
pH approx. 6.8) from Bio-Rad. The mixture was heated
in boiling water for 2 minutes and immediately loaded on
the gel. The SDS-PAGE gel was composed of a stacking
gel (125 mM Tris-HCl, pH6.8, 0.1% SDS) with a large-
pore polyacrylamide gel (4%) cast over the resolving gel
(4-20% acrylamide gradient in 375 mM Tris-HCl, pH8.8,
0.1% SDS buffer). The cathodic and anodic compart-
ments were filled with Tris-glycine buffer, pH8.3, con-
taining 0.1% SDS. The electrophoretic run was done at
100 V until the dye front reached the bottom of the gel.
Staining and de-staining were performed using the Col-
loidal Coomassie Blue staining kit from Invitrogen
(Carlsbad, CA, USA). Putative blue bands were excised
and split in two. The smallest part (one fourth) was to
confirm the presence of the 12 030 Da biomarker by
SELDI-TOF MS (NP20 array), after protein extraction
with a solution of formic acid (5 vol)-acetonitrile
(2.5 vol)-2-propanol (1.5 vol)-water (1 vol) for 2 hours at
room temperature. The other part (three fourth) was
trypsinized for protein identification by Liquid Chroma-
tography MS/MS (LC-MS/MS) (see details in the corre-
sponding section).
Analysis of crude and purified fractions by SELDI-TOF MS
After protein extraction, fractions at appropriate con-
centration, i.e.0 . 0 2μg/μL, were deposited upon Pro-
teinChip® array surfaces, using a Bioprocessor device.
Two types of arrays were selected: CM10 (weak cation
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Assisted Laser Desorption Ionization time of flight,
MALDI-TOF mode). Each array contained eight distinct
spots over which the adsorption of protein could be per-
formed. After applying the samples, the chip surfaces
were washed to remove non-associated protein (only for
CM10 arrays) and then dried and prepared for analysis
after application of 1 μLo fe n e r g ya d s o r b i n gm a t r i x
solution composed of a saturated solution of sinapinic
acid in 50% acetonitrile and 0.5% trifluoroacetic acid.
All arrays were then analyzed with a PCS 4000 Pro-
teinChip® MS reader. The instrument was used in a
positive ion mode, with an ion acceleration potential of
20 kVolts and a detector gain voltage of 2 kVolts. The
mass range investigated was from 3 kDa to 20 kDa. The
laser intensity was set between 200 and 250 units
according to the sample tested. The instrument was
mass calibrated with a kit of standard mass mixture
“All-in-1 protein standard” (Bio-Rad).
Protein identification by LC-MS/MS
Putative blue bands manually excised from the gel were
sent to the Functional Proteomic Platform in Montpel-
lier (INRA, France) and protein identification was done
according to a standard operating procedure. Tryptic
peptides were analyzed by an ESI-Ion Trap mass spec-
trometer (Esquire HCT; Bruker Daltonik GmbH, Bre-
men, Germany), interfaced with an HPLC-Chip system
(Agilent Technologies, Palo Alto, CA). A sample volume
of 2 μl was loaded onto a C-18 enrichment cartridge
(40 nL) with a flow rate of 0.3 μl/min of 0.1% (v/v) for-
mic acid. After pre-concentration and clean-up, peptides
were separated in the column (HPLC-Chip C18, 5 μm,
75 μmx43 mm, 40 nL enrichment column; Agilent
Technologies, Palo Alto, CA) at a flow rate of 4 μl/min
using a gradient of 3% to 80% (v/v) acetonitrile in 15
minutes (0.1% [v/v] formic acid). Peptides were eluted
into the High Capacity ion Trap (Esquire HCT; Bruker
Daltonik GmbH, Bremen, Germany). Capillary voltage
was 1.5-2 kVolts in the positive ion mode and a dry gas
flow rate of 4.5 L/minute with a temperature of 250 °C
was used. The first full-scan mass spectrum was mea-
sured for a range from 310 to 1800 m/z. The second
scan was done to exactly measure the Mr of the three
major ions with higher resolution and the third scan to
measure the collision-induced MS/MS spectrum of the
selected ions. Theorical peptide values were obtained
from UniProt database [56], the corresponding access
number of ovine transthyretin is P12303.
Results
Reproducibility study
First, to evaluate the reproducibility of SELDI-TOF MS
analyses, 10 μg of proteins from a human serum control
(Ciphergen Biosystems) were spotted onto three CM10
ProteinChip® arrays at the same time. The mass spectra
were analyzed in the 2-20 kDa range by SELDI-TOF MS
under identical conditions in the same day (Figure 1). A
range of 120 to 130 peaks were found in the three
experiments. The peak number variations detected in
t h e2 - 2 0k D ar a n g e( s i g n a l / n o i s er a t i oo fa tl e a s t5 )
among samples were 7.69% (10/130) and the coefficient
of variation of peak intensities was lower than 25%. The
mass accuracy for such molecular weight was comprised
between 0.1 and 0.2%. This test was performed before
the analysis of sheep and hamster samples.
Detection by SELDI-TOF MS of proteins which are
differentially expressed in scrapie
To detect biomarkers characteristic of the EP and LP of
scrapie in sheep, we carried out a SELDI-TOF MS analy-
s i so ft h ep r o f i l e so fp r o t e i n si n c l u d e di nt h e2 - 2 0k D a
range in the anion-exchange fractions (at pH9, pH7,
pH5, pH4 and pH3 and the organic wash) obtained from
serum samples of sheep with (EP or LP) scrapie and
healthy controls (Table 1) (see Figure 2 for representative
PrP
ARR/PrP
ARR sheep protein profiles of the different
fractions). The majority of peaks were found to have a
mass smaller than 10 kDa and few peaks were detected
in the high mass molecular weight, above 20 kDa (data
not shown). A total of 95 qualified mass peaks were
detected by the Ciphergen Biosystems Software 3.2.1 for
a l ls p e c t r aa n dw e r ea n a l y z e di na ne x p r e s s i o nm a t r i x .
Differential analysis of peak intensities was conducted
using the SAM method (Table 2).
First, 55 serum samples from 7-9 month/old animals in
the EP of scrapie, which had been classified as PrP
VRQ/
PrP
VRQ, were compared to 65 serum samples from healthy
PrP
ARR/PrP
ARR sheep. The EP of scrapie infection is very
important for diagnostic purposes as the clinical symp-
toms are not apparent yet and the pathological agent
PrP
Sc is moving from lymphoid organs to the brain. Seven
peaks were found to be differentially expressed in EP ani-
mals in comparison to controls and four of them (i.e., S1
4030 Da, S2 4250 Da, S3 7475 Da and S4 9395 Da) were
considered to be the best candidates as biomarkers of EP
scrapie (see SELDI profiles in Figure 3, and Table 2). Spe-
cifically, three of these peaks (S1, S3 and S4) were over-
expressed and one (S2) was under-expressed in EP sheep
compared to controls. Their significant SAM values were
≥ 3.40 and the fold change was ≥ 1.75 or 0.5 with a null
q-value. Moreover, the biomarker accuracy test (ROC) of
the four peaks showed an AUC > 0.717 with the following
individual values: 0.771 (S1), 0.735 (S2), 0.741 (S3) and
0.717 (S4). The distribution of the intensity values for the
S1 to S4 biomarkers in control and EP sheep populations
(Figure 4A) confirmed that S1, S3 and S4 were signifi-
cantly over-expressed and S2 under-expressed in EP sheep
in comparison to healthy controls.
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PrP
VRQ/PrP
VRQ sheep with LP scrapie were compared
to the 65 serum samples from healthy, PrP
ARR/PrP
ARR
animals. In LP scrapie, animals develop clinical symp-
toms (fear, nervousness, ataxia of the hind limbs, nib-
bling and licking) as the central nervous system is
affected. Among the ten peaks differentially expressed in
LP animals, four (i.e., S1 4030 Da, S5 3895 Da, S6 7690
Da and S7 9425 Da) were chosen as putative LP biomar-
kers (see Table 2 for statistical data). Three peaks (S1,
S6 and S7) were over-expressed and one peak (S5) was
under-expressed in LP sheep compared to controls.
Their significant SAM values were ≥ 1.44 and the fold
change was ≥ 1.26 or 0.38. Moreover, the biomarker
accuracy test (ROC) of the four peaks showed an AUC
> 0.617 with the following individual values: 0.617 (S1),
0.702 (S5), 0.659 (S6) and 0.693 (S7). The distribution of
the intensity values of S1, S5, S6 and S7 (Figure 4B)
confirmed the over-expression of markers S1, S6, S7
and the under-expression of marker S5 in LP sheep in
comparison to healthy controls.
In conclusion, 7 peaks were found to significantly dif-
ferentiate EP from control or LP animals and 10 peaks
to significantly discriminate LP from control or EP ani-
mals. All together 15 different peaks were selected and
2 peaks (S1 and S13) were found to be significant in
both phases of the disease.
EP and LP biomarkers panel best combination
The previous data indicate that none of the selected bio-
markers is sensitive and specific enough to be used as a
single signature biomarker of scrapie in EP or in LP.
We thus used the mROC program to test whether the
combination of the four best EP (S1-S2-S3-S4) or of the
four best LP (S1-S5-S6-S7) biomarkers could improve
their diagnostic accuracy (Figure 5). The analysis of the
ROC curve for the EP combination gave a better AUC
(0.943) compared with the AUCs of the individual bio-
markers and this combination showed a sensitivity of
87.3% and a specificity of 90.8%. Conversely, the panel
of LP biomarkers reached only a sensitivity of 69.8% and
a specificity of 76.9%; however, its AUC of 0.762 was
better than the one of the single biomarkers, confirming
that the combined set of LP biomarkers was more reli-
able than the individual biomarkers.
AdaBoost and SVM were also used to evaluate the
potential diagnostic characteristics of our set of biomar-
kers. The Se and Sp values obtained with AdaBoost and
SVM were comparable to those obtained with mROC
(Table 3). Specifically, when control sheep were com-
pared to EP sheep all methods generated results closed
to the mROC values with an average specificity and sen-
sitivity of 88.1% and 87.3% respectively. When control
sheep were compared to LP sheep, the obtained Se and
Sp values were more variable with an average specificity
Figure 1 Reproducibility of SELDI-TOF MS analysis using a human serum control. A human serum control was fractionated three times on
consecutive days and then the organic fraction F6 spotted and analyzed by SELDI-TOF MS in the range of 2-20 kDa on the same day.
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case, Adaboost (accuracy = 0.780) seemed to perform
better than SVM (accuracy = 0.729). We investigated
the possible correlation of S1 to S7 biomarkers with sex
and the corresponding p-values were obtained according
to one-way ANOVA with a no significant value of more
than 0.05.
Analysis of the appearance of serum biomarkers in
VRQ/VRQ Cheviot TSE free sheep
To test whether the 4 best combined EP biomarkers (S1
to S4) and the 4 best combined LP biomarkers (S1, S5,
S6 and S7) presented in table 2 could be significant in
another sheep, we analyzed serum samples from 3
VRQ/VRQ Cheviot TSE free sheep (negative controls).
Sera were fractionated and analyzed in the 2-20 kDa
range using CM10 Proteinchips®. The SELDI-TOF MS
protein profiles of fractionated serum from negative
controls (n = 3) and infected EP sheep (n = 3) were sig-
nificantly different, focusing independently on each bio-
marker of interest (Figure 6). Minor or no differences
were observed comparing the LP biomarkers on SELDI-
TOF MS protein profiles of fractionated serum samples
from negative control sheep (n = 3) with those from LP
Figure 2 Representative fractionated serum SELDI-TOF MS protein profiles of a PRP
ARR/ARR sheep. F1 (pH9), F2 (pH7), F3 (pH5), F4 (pH4),
F5 (pH3), F6 (organic wash).
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Page 7 of 17sheep (n = 3). These results show that the best combi-
nation of EP biomarkers could be significant comparing
serum samples collected from animals from different
laboratories. Furthermore, these results suggest that the
EP signature pattern is correlated to the disease and not
to the genotype. Still, an increased number of serum
samples from TSE free sheep is necessary to further
confirm theses observations.
Analysis of the appearance of serum biomarkers in
hamsters infected with the 263 K scrapie strain
To test whether the 15 biomarkers (S1 to S15) pre-
sented in table 2, including biomarkers specific for EP
and LP phase of scrapie could be detected in another
species using the same technology, we infected ten Syr-
ian hamsters, in which the course of the disease is
much more rapid than in sheep, with the 263 K scrapie
strain and collected serum at different time points (day
0, 29, 57, 106 and 150 post-infection) during disease
progression. As with the sheep samples, hamster sera
(diseased and healthy controls) were fractionated and
each anion-exchange fraction (pH9, pH7, pH5, pH4,
pH3 and the organic wash) was analyzed in the 2-20
kDa range using CM10 Proteinchips® under identical
conditions and in the same day. The SELDI-TOF MS
protein profiles of serum from Syrian hamsters were
different from those of sheep (Figure 7 and compare
with Figure 2). Nevertheless, the mass of three of the
fifteen sheep candidate biomarkers could be detected in
the hamster protein profile: S10 (named H1, found in
F6 in the hamster model), S5 (named H2, found in F2
in the hamster model) and S12 (named H3, found F1 in
the hamster model). Their intensity was followed
throughout the course of the disease and two different
behaviors could be observed. The intensity of peak H1
increased early after infection and continued to grow in
a regular way (Figure 8A). Conversely, the intensity of
peak H2 and H3 remained stable and dramatically
i n c r e a s e do n l ya tt h ev e r ye n do ft h eL Po fd i s e a s e
(almost before the death of the animals) (Figures 8B
and 8C). These results suggest that also in the hamster
model of scrapie it is possible to distinguish between
proteins which are differentially expressed in the EP of
the disease (H1) in comparison to healthy controls and
proteins which are characteristic of the LP of infection
(H2 and H3).
Identification and validation of S10 biomarker in sheep
We focused our interest on the H1 peak which could be
considered as an early biomarker of disease in the hamster
model. H1 had a mass of 12 030 Da which corresponded
to that of peak S10 in sheep. However, while in the ham-
ster model H1 was over-expressed, in sheep S10 was
down-regulated and it was classified as a marker of LP
scrapie (Table 2). With the aim of understanding the rea-
son of this discrepancy, we decided to identify in sheep
serum the protein composition of this peak. We first per-
formed purification and enrichment (see Materials and
Methods) of the 12 030 Da biomarker obtained from
selected resins (Figure 9). The 12 030 Da biomarker was
successfully enriched and amplified after scaling up by 100
folds the sample load on selective resins. Step gradient
elution using optimal conditions also improved markers
purity. The final step of the purification consisted in
Table 2 List of the 15 biomarkers that were differentially expressed in scrapie sheep in comparison to control animals
Markers Mass (Da) Fraction Variation Healthy (n = 65) vs EP (n = 55) Healthy (n = 65) vs LP (n = 43)
FDR (%) SAM FC AUC FDR (%) SAM FC AUC
S1 4030 F4 over 0,00 4,72 1,81 0,771 13,01 1,44 1,44 0,617
S2 4250 F1 under 0,00 -3,56 0,53 0,735 ND ND ND ND
S3 7475 F3 over 0,00 3,39 1,75 0,741 ND ND ND ND
S4 9395 F3 over 0,00 4,21 1,89 0,717 ND ND ND ND
S5 3895 F6 under ND ND ND ND 15,34 -1,99 0,38 0,702
S6 7690 F6 over ND ND ND ND 0,00 2,31 1,26 0,659
S7 9425 F6 over ND ND ND ND 0,00 3,07 1,49 0,693
S8 27450 F6 over ND ND ND ND 4,77 2,20 1,39 0,672
S9 13670 F5 over ND ND ND ND 0,00 3,15 1,39 0,683
S10 12030 F6 under ND ND ND ND 10,74 -2,91 0,79 0,625
S11 8350 F6 over ND ND ND ND 4,77 2,12 1,19 0,648
S12 7555 F1 over ND ND ND ND 0,00 2,63 1,16 0,648
S13 4575 F3 over 0,00 3,42 1,38 0,668 0,00 2,83 1,18 0,671
S14 9180 F3 over 0,00 3,98 2,00 0,707 ND ND ND ND
S15 6815 F4 under 3,34 -2,40 0,81 0,637 ND ND ND ND
These peaks were selected according to their False Discovery Rate (FDR), their Fold Change (FC), their AUC ROC and the SAM test. The peak S1 and S13 were
significant both in EP and LP; S2, S3, S4, S14 and S15 were significant in EP; S5, S6, S7, S8, S9, S10, S11 and S12 were significant in LP. ND: Non determined, only
for non significant values.
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Page 8 of 17SDS-PAGE separation and SELDI-TOF MS analysis of the
selected 12 030 Da band which was visible after colloidal
blue staining thanks to the 100 fold scale-up amplification
(Figure 10). Finally, using LC-MS/MS analysis, the S10
peak was identified as a major fragment (37 amino acids)
of the transthyretin monomer (147 amino acids, P12303).
The corresponding peptides are described in Figure 11
and the sequence coverage of the protein is 29.4%. The
transthyretin protein in hamster (84 amino acids,
B3VTM4) presents 94% of similarities with the sheep one
and 91% considering the fragment of interest correspond-
ing to S10 biomarker. Furthermore, we investigated the
reproducibility of S10 under-expression and H1 over-
expression by western blot analysis (see additional file 1:
Transthyretin western blot analysis in serum from 3 LP
sheep (VRQ/VRQ) and 3 healthy sheep (ARR/ARR);
additional file 2: Transthyretin western blot analysis in
serum (F6) from 2 Syrian hamsters at different kinetic
points of the scrapie 263 K infection). The results showed
an under-expression of the transthyretin monomer, dimer
and tetramer (circulating forms of transthyretin) in serum
from healthy sheep comparing to the same isoforms in
serum from LP sheep. In hamsters infected by scrapie, we
found the expression of the monomer isoform increasing
with the time of infection. We also determined the trans-
thyretin protein level in serum from healthy sheep (n =
20), EP sheep (n = 10) and LP sheep (n = 11) (see addi-
tional file 3: Quantitative analysis of serum levels of trans-
thyretin). Total transthyretin protein concentration is
significantly decreased in LP sheep (fold change median =
1.46 and p-value < 0.001) whereas it is not in EP sheep
(fold change median = 1.11 and p-value > 0.1). All these
Figure 3 Representative SELDI-TOF MS protein profiles of serum samples from three healthy animals and three scrapie sheep.( A )
Representation of the 4030 Da protein (S1) contained in F4. (B) Representation of the 4250 Da (S2) protein contained in F6. (C) Representation
of the 7475 Da (S3) protein contained in F3. (D) Representation of the 9395 Da (S4) protein contained in F1.
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Page 9 of 17observations correlate to the SELDI-TOF MS analysis. The
curve representations of total ovine transthyretin concen-
trations fluctuation in healthy and pathological sheep indi-
cate that transthyretin under-expression is not correlated
with the age.
Discussion
In this study, we report the first analysis of potential bio-
markers in serum of sheep during the first 7 to 10 months
o fs c r a p i ei n f e c t i o n .O u rr e s u l t si n d i c a t et h a tw eh a v e
detected a biomarker profile which could be used to diag-
nose scrapie in sheep with no apparent symptoms during
the incubation phase of the disease. This is important as
access to serologic markers can avoid invasive acts as
biopsy or lumbar punction; however, complementary
research is needed to confirm the real relevance of these
proteins as TSEs biomarkers. Particularly, age matching
is not fully balanced since it was difficult to find a large
Figure 4 Representative distribution of the intensities of selected biomarkers in the sheep populations. (A) Distribution of biomarkers S1
to S4 in control and EP sheep populations. (B) Distribution of biomarkers S1 and S5 to S7 in control and LP sheep populations. The thick line in
the boxes indicates the median value of intensities for each population.
Figure 5 mROC graph representations of sensitivities and specificities of the combination of EP (black curve) or LP (grey curve)
biomarkers. The mROC linear equations for decision rule are ZEP = -1.547 × [S2*] +0.466 × [S3*] + 0.661 × [S4*] + 1.238 × [S1*]; ZLP = 0.295 ×
[M1*] + 0.397 × [M5*] + 0.176 × [M6] + 0.399 × [M7*] * with lS1= 0.05, lS2 = -0.17, lS3 = 0.32, lS4 = 0.44, lS5 = -0.18, lS7 = 0.01 where l is the
coefficient of Box-Cox transformation: (S* = (S
l-1)/l)
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Page 10 of 17cohort of young control sheep. A validation study with
age-matched animals will permit to confirm the robust-
ness of the results. The main bottle-neck of SELDI-TOF
MS profiling technology is the purification and the iden-
tification of individual proteins, therefore we need to
concentrate our resources on biomarkers that are most
likely to be biologically significant, such as the 4-protein
signature we detected in EP sera. Conversely, the specifi-
city and sensitivity of the combination of LP markers is
not sufficient enough to exploit them further.
The kinetic study of the proteomic content of sera from
hamsters infected with the 263 K scrapie strain allowed
the detection of three differentially expressed peaks (H1,
H2, H3). H1 increased early and regularly during the
Table 3 Diagnostic performances of biomarkers combination using three different classifiers
Classifiers Healthy (n = 65) Vs EP (n = 55) Healthy (n = 65) Vs LP (n = 43)
Accuracy Se Sp Accuracy Se Sp
mROC 0,891 87,3 90,8 0,741 69,8 76,9
AdaBoost 0,867 86,6 86,8 0,780 82,5 71,1
SVM 0,873 88,0 86,8 0,729 56,5 83,7
The different classifiers used were: SVM (Kernel = radial, gamma = 0.2); Adaboost (weak learner: Decision stump, iteration = 100, weight tresholdEP = 50, weight
tresholdLP = 85) and mROC.
Figure 6 Representative SELDI-TOF MS protein profiles of serum samples from three negative control TSE free sheep and three EP
scrapie sheep. (A). Representation of the 4030 Da protein (S1) contained in F4. (B) Representation of the 4250 Da (S2) protein contained in F6.
(C) Representation of the 7475 Da (S3) protein contained in F3. (D) Representation of the 9395 Da (S4) protein contained in F3.
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Page 11 of 17course of the disease, whereas H2 and H3 increased sud-
denly at very end of the infection process. None of these
biomarkers was found to increase in control, not infected
hamsters. Interestingly, S10 and H1 have the same mole-
cular mass, but their intensities vary differently in sheep
and in hamsters along time. S10 was then identified as a
fragment of the transthyretin monomer. Transthyretin or
pre-albumin is a homo-tetramer glycoprotein synthesized
by liver and present in plasma, serum and cerebrospinal
fluid. It has a molecular mass of 55 kDa and is the main
thyroxin and vitamin A transporter. Transthyretin is an
early marker of under-nutrition; its plasma level is
decreased in case of liver failure, inflammatory syndrome
and increased in case of chronic renal insufficiency. Trans-
thyretin was already quoted in literature as a molecule
associated with neurological disorders like multiple sclero-
sis [57], amyloid polyneuropathy [58-60] and TSEs [61]. It
has been previously described as a Creutzfeldt-Jakob dis-
ease biomarker detectable in the cerebrospinal fluid [62].
Furthermore, several proteins linked to neurodegenerative
diseases, such as amyloid beta, tau, prions and transthy-
retin, were found to be glycated in patients, and this is
Figure 7 Representative fractionated serum SELDI-TOF MS protein profiles of Syrian hamster infected with the 263 K scrapie strain
(day 29 post-infection): F1 (pH9), F2 (pH7), F3 (pH5), F4 (pH4), F5 (pH3), F6 (organic wash).
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Page 12 of 17thought to be associated with increased protein stability
through the formation of crosslinks that stabilize protein
aggregates [63]. A proteic characterization of the trans-
thyretin fragment found discriminant in our study can
provide useful informations for TSEs diagnostic. The
molecular mass of the transthyretin monomer is 15.7 kDa;
therefore by SELDI-TOF MS we detected a major frag-
ment of the monomer. In scrapie sheep, its intensity
decreased with the disease, whereas it increased in infected
hamsters. Furthermore, sample handling can play a role
in proteomics variations [64]. Finally, since in hamsters
scrapie is not a naturally occurring disease, different
Figure 8 Representative distribution of the intensities of selected biomarkers in Syrian hamsters infected with the 263 K scrapie
strain: (A) H1 (12 030 Da), (B) H2 (3895 Da) and (C) H3 (7555 Da) at day 0, day 29, day 57, day 106, day 150 post-infection.
Figure 9 Selection of complementary and selective resins for the 12 030 Da biomarker.
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Page 13 of 17pathological mechanisms, and hence different protein sig-
natures, could play a role in the development of the dis-
ease. Unfortunately, due to volume limitations, we could
not identify the 12 030 Da SELDI peak in hamster serum
for cross-validation. The transthyretin analysis done by
western blot and serum level quantification confirmed the
SELDI-TOF MS results. In a recent study, a training set of
biomarkers has been established in brain homogenate
samples from a murine model infected by the ME-7 scra-
pie strain [65]. Two of the biomarkers found discriminant
in the infected animals compared to controls may corre-
spond in m/z to the biomarkers S12, H3 (7555 Da) and
S14 (9180 Da). Their fluctuation is inversely correlated
with S12 and S14, confirming that depending on
the model and the time course study, biomarkers can be
significantly down or up regulated and that protein
Figure 10 SDS-Page separation and SELDI-TOF MS analysis of the purified 12 030 Da biomarker: 0.5 ml of F6 fraction after overload on
10 μl selective resin was used.
Figure 11 Ovine and hamster transthyretin sequences: peptides identified by LC-MS/MS are highlighted. (+) represent amino acids with
similar physico-chemical properties.
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Page 14 of 17expression in TSE disease exist across different species.
The biomarkers we identified can be used as a target of
development of future immunobased assay more suitable
for veterinary or clinical analysis and compatible with
blood screening.
Conclusion
Currently, the quest of non invasive TSEs biomarkers
remains important and the development of a rapid, sensi-
tive, specific, ante-mortem test is still needed. Indeed, a
recent report detailed that prions adhere to soil minerals
and remain infectious [66] such that unidentified envir-
onmental reservoirs of infectivity contribute to the nat-
ural transmission of prion diseases in sheep, deer and elk.
Although the pandemic infection is now minimized, we
need to remain vigilant to prevent a new crisis. The
development of non-prion protein biomarkers for TSEs
has been reported recently due to the advances in post-
genomic technologies. However, more work needs to be
done to confirm the specificity and sensitivity of bioas-
says combining the identified biomarkers. The remaining
steps will be to design specific probes against biomarkers
and optimize bioassay condition. Then, large scale valida-
tion would be affordable. These steps are mandatory to
envision a future peripheric TSE bioassay.
Additional material
Additional file 1: Transthyretin western blot analysis in serum from
3 LP sheep (VRQ/VRQ) and 3 healthy sheep (ARR/ARR). Fifty μgo f
proteins from serum samples have migrated on a SDS-Page acrylamide
12% electrophoretic gel (lines 1 to 3: pathological VRQ/VRQ sheep; lines
4 to 6: healthy ARR/ARR sheep; border line control “Ctl": 100 ng of
Recombinant full length Human Prealbumin, amino acids 21-147, 13,8
kDa abcam n°92931). The transthyretin signal is revealed by a primary
polyclonal antibody from rabbit (abcam n°16006; immunogen =
prealbumin isolated from human plasma; reacts with human, sheep)
used at 1 μg/mL in 0.1% PBS-Tween/2% milk and a secondary antibody
coupled with HRP diluted 1/80 000 in 0.1% PBS-Tween/2% milk. The
molecular weight standards are mentioned in kilo Dalton (Bio-Rad).
Additional file 2: Transthyretin western blot analysis in serum (F6)
from 2 Syrian hamsters at different kinetic points of the scrapie 263
K infection. Ten μg of proteins from serum samples (F6) from infected
Syrian hamsters have migrated on a SDS-Page acrylamide 12%
electrophoretic gel (lines 2 to 5: kinetic points J0, J29, J57, J106 of hamster
n°1; l ines 6 to 9: kinetic points J29, J57, J106, J150 of hamster n°2; border
line control “Ctl": 100 ng of recombinant transthyretin protein). The
transthyretin signal is revealed by a primary polyclonal antibody from
rabbit used at 1 μg/mL in 0.1% PBS-Tween/2% milk and a secondary
antibody coupled with HRP diluted 1/80 000 in 0.1% PBS-Tween/2% milk.
The signal corresponding to the transthyretin fragment is localized on the
gel between the molecular weigth proteins 10 and 25 kDa.
Additional file 3: Quantitative analysis of serum level of
transthyretin. Box plot representation of total ovine transthyretin
concentrations in serum from healthy sheep (ARR/ARR), EP sheep (VRQ/
VRQ) and LP sheep (VRQ/VRQ) populations. The median fold change is
1.11 comparing the median concentration values of serum from healthy
sheep versus EP sheep and 1.46 comparing the median concentrations
values of serum from healthy sheep versus LP sheep. The median
concentration value of transthyretin in serum from healthy sheep is
252.80 μg/mL, in EP sheep 227.60 μg/mL and in LP sheep 172.80 μg/mL.
Kaleidagraph 4.0 software was used to calculate the p value (Wilcoxon
test) and to present the boxplot graphs. Curve representation of total
ovine transthyretin concentration fluctuation in serum from healthy
sheep (ARR/ARR). Curve representation of total ovine transthyretin
concentration fluctuation in serum from pathological sheep (VRQ/VRQ).
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